Genital herpes: Antiviral therapy for symptom relief and prevention of transmission

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 6, 2006, Pages 665-675

  Gupta, Rachna ^a   Wald, Anna ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acyclovir; Episodic; Famciclovir; Genital herpes; Herpes simplex virus type 2; Prevention; Recurrence; Valacyclovir

Indexed keywords

ACICLOVIR; ACICLOVIR TRIPHOSPHATE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; PENCICLOVIR; PENCICLOVIR TRIPHOSPHATE; TRIFLURIDINE; VALACICLOVIR; VIDARABINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; BURNING SENSATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GENITAL HERPES; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; KIDNEY DYSFUNCTION; NAUSEA; NEPHROTOXICITY; PAIN; PATIENT COUNSELING; PATIENT EDUCATION; PRURITUS; RECURRENT VIRUS INFECTION; REVIEW; SHORT COURSE THERAPY; SYMPTOMATOLOGY; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS TRANSMISSION;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS; FEMALE; HERPES GENITALIS; HUMANS; MALE; VALINE;

EID: 33645829043     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.6.665     Document Type: Review

References (80)

1. FLEMING D, MCQUILLAN G, JOHNSON R et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. (1997) 337(16):1105-1111.
2. LEONE P, FLEMING DT, GILSENAN AW, LI L, JUSTUS S: Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex. Transm. Dis. (2004) 31(5):311-316.
3. WALD A, KOUTSKY L, ASHLEY R, COREY L: Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infection. Sex. Transm. Dis. (1997) 24:149-155.
4. CHERPES TL, MEYN LA, KROHN MA, HILLIER SL: Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex. Transm. Dis. (2003) 30(5):405-410.
5. NAHMIAS A, LEE F, BECKMA-NAHMIAS S: Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J. Infect. Dis. (1990) 69:19-36.
6. CROSBY RA, DICLEMENTE RJ, WINGOOD GM, ROSE E: Testing for HSV-2 infection among pregnant teens: implications for clinical practice. J. Pediatr. Adolesc. Gynecol. (2003) 16(1):39-41.
7. GOTTLIEB SL, DOUGLAS JM Jr, SCHMID DS et al.: Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J. Infect. Dis. (2002) 186(10):1381-1389.
8. AUSTIN H, MACALUSO M, NAHMIAS A et al.: Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Sex. Transm. Dis. (1999) 26(6):329-334.
9. KOUTSKY LA, ASHLEY RL, HOLMES KK et al.: The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. (1990) 17:90-94.
10. MERTZ GJ, SCHMIDT O, JOURDEN JL et al.: Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Transm. Dis. (1985) 12:33-39.
11. COREY L, WALD A: Genital herpes (Ch. 21). In: Sexually Transmitted Diseases J Wasserheit (Ed.), McGraw-Hill, New York, NY, USA (1999):285-312.
12. COREY L, WALD A, CELUM CL, QUINN TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defec. Syndr. (2004) 35(5):435-445.
13. COREY L, HOLMES KK: Genital herpes simplex virus infection: current concepts in diagnosis, therapy and prevention. Ann. Intern. Med. (1983) 98:973-983.
14. WALD A: New therapies and prevention strategies for genital herpes. Clin. Infect. Dis. (1999) 28:S4-S13.
15. BRYSON YJ, DILLON M, LOVETT M et al.: Treatment of first episodes of genital herpes simplex virus infections with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. (1983) 308:916-920.
16. MERTZ G, CRITCHLOW C, BENEDETTI J et al.: Double-blind placebo-controlled trial of oral acyclovir in the first episode genital herpes simplex virus infection. JAMA (1984) 252:1147-1151.
17. REITANO M, TYRING S, LANG W et al.: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis. (1998) 178:603-610.
18. DIAZ-MITOMA F, SIBBALD RG, SHAFRAN SD et al.: Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA (1998) 280:887-892.
19. COREY L, WALD A, PATEL R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. (2004) 350(1):11-20.
20. MINDEL A, WELLER I, FAHERTY A et al.: Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin. Med. (1986) 62(1):28-32.
21. FIFE KH, CRUMPACKER CS, MERTZ GJ et al.: Recurrence and resistance patterns of herpes simplex virus following cessation of > 6 years of chronic suppression with acyclovir. J. Infect. Dis. (1994) 169:1338-1341.
22. HAYDEN FG: Antimicrobial agents: antiviral agents. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. JG Hardman, LE Limbird, AG Goodman (Eds), McGraw-Hill, New York, NY, USA (2001):1313-1348.
23. TYRING SK, BAKER D, SNOWDEN W: Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J. Infect. Dis. (2002) 186(Suppl. 1):S40-S46.
24. GOLDBERG LH, KAUFMAN R, KURTZ T et al.: Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch. Dermatol. (1993) 129:582-587.
25. WALD A, BENEDETTI J, DAVIS G et al.: A randomized, double-blind, comparative trial comparing high and standard dose oral acyclovir for first-episode genital herpes infections. Antimicrob. Agents Chemother. (1994) 38:174-176.
26. BELL W, CHULAY J, FEINBERG J: Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (1997) 76:369-380.
27. SACKS S: Use of penciclovir and famciclovir in the management of genital herpes. Curr. Probl. Dermatol. (1996) 24:219-226.
28. LOVELESS M, HARRIS W, SACKS S: Treatment of first episode genital herpes with famciclovir. Programmes and Abstracts of the 35th Interscience Conference on Antimicrob. Agents Chemother. San Francisco, CA, USA (1995).
29. SCHACKER T, HU HL, KOELLE DM et al.: Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128(1):21-28.
30. CDC: Sexually transmitted disease treatment guidelines 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(RR-6):12-17.
31. SACKS SL, AOKI FY, DIAZ-MITOMA F, SELLORS J, SHAFRAN SD: Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA (1996) 276:44-49.
32. ROMANOWSKI B, AOKI FY, MARTEL AY et al.: Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. Aids (2000) 14(9):1211-1217.
33. HENRY RE, WEGMANN JA, HARTLE JE, CHRISTOPHER GW: Successful oral acyclovir desensitization. Ann. Allergy (1993) 70(5):386-388.
34. KAWSAR M, PARKIN JM, FORSTER G: Graded challenge in an aciclovir allergic patient. Sex. Transm. Infect. (2001) 77(3):204-205.
35. SAFRIN S, CRUMPACKER C, CHATIS P et al.: A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. (1991) 325:551-555.
36. LALEZARI J, SCHACKER T, FEINBERG J et al.: A randomized, double-blind, placebo-controlled trial of cidofovir topical gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex infection in patients with AIDS. J. Infect. Dis. (1997) 176:892-898.
37. KESSLER H, HURWITZ S, FARTHING C et al.: Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 12:147-152.
38. MURPHY M, MORLEY A, EGLIN R, MONTEIRO E: Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient. Lancet (1992) 340:1040.
39. KOUTSKY LA, STEVENS CE, HOLMES KK et al.: Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N. Engl. J. Med. (1992) 326:1539-1553.
40. COREY L, ADAMS HG, BROWN ZA, HOLMES KK: Clinical course of genital herpes simplex virus infections in men and women. Ann. Intern. Med. (1983) 48:973.
41. LAFFERTY WE, KROFFT S, REMINGTON M et al.: Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high prevalence population. J. Clin. Microbiol. (1987) 25:323-326.
42. RAMASWAMY M, MCDONALD C, SMITH M et al.: Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex. Transm. Infect. (2004) 80(5):406-410.
43. ASHLEY RL, WALD A: Genital herpes: review of the epidemic and potential use of type- specific serology. Clin. Microbiol. Rev. (1999) 12(1):1-8.
44. COREY L: Challenges in genital herpes simplex virus management. J. Infect. Dis. (2002) 186(Suppl. 1):S29-S33.
45. GOLDEN MR, ASHLEY-MORROW R, SWENSON P, HOGREFE WR, HANDSFIELD HH, WALD A: HSV-2 western blot confirmatory testing among men testing positive for HSV-2 using the focus ELISA in an STD clinic. Sex. Transm. Dis. (2005) 32(12):771-777.
46. COREY L, BENEDETTI J, CRITCHLOW C et al.: Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J. Antimicrob. Chemother. (1983) 12(Suppl. B):79-88.
47. COREY L, FIFE KH, BENEDETTI JK et al.: Intravenous acyclovir for the treatment of primary genital herpes. Ann. Intern. Med. (1983) 98:914-921.
48. BRYSON YJ, DILLON M, LOVETT M et al.: Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. (1983) 308(16):916-921.
49. BENEDETTI JK, COREY L, ASHLEY R: Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. (1994) 121:847-854.
50. ENGELBERG R, CARRELL D, KRANTZ E, COREY L, WALD A: Natural history of genital herpes simplex virus type 1 infection. Sex. Transm. Dis. (2003) 30(2):174-177.
51. BODSWORTH NJ, CROOKS RJ, BORELLI S et al.: Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. International Valaciclovir HSV Study Group. Genitourin. Med. (1997) 73:110-116.
52. TYRING SK, DOUGLAS JM, COREY L, SPRUANCE SL, ESMANN J: A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. International Valaciclovir HSV Study Group. Arch. Dermatol. (1998) 134:185-191.
53. CHOSIDOW O, DROUAULT Y, LECONTE-VEYRIAC F et al.: Famciclovir versus aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br. J. Dermatol. (2001) 144(4):818-824.
54. WALD A, CARRELL D, REMINGTON M et al.: Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis. (2002) 34(7):944-948.
55. STRAND A, PATEL R, WULF HC, COATES KM: Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex. Transm. Infect. (2002) 78(6):435-439.
56. AOKI FY, TYRING S, DIAZ-MITOMA F, GROSS G, GAO J, HAMED K: Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. (2006) 42(1):8-13.
57. PATEL R, TYRING S, STRAND A, PRICE MJ, GRANT DM: Impact of suppressive antiviral therapy on the health-related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect. (1999) 75:398-402.
58. ROMANOWSKI B, MARINA RB, ROBERTS JN: Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex. Transm. Dis. (2003) 30(3):226-231.
59. STRAUS S, TAKIFF H, SEIDLIN M et al.: Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N. Engl. J. Med. (1984) 310:1545-1550.
60. DOUGLAS J, CRITCHLOW C, BENEDETTI J et al.: A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. (1984) 310:1551-1556.
61. MINDEL A, CARNEY O, FRERIS M et al.: Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet (1988) 1:926-928.
62. MERTZ GJ, LOVELESS MO, LEVIN MJ et al.: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch. Intern. Med. (1997) 157:343-349.
63. BENEDETTI JK, ZEH J, COREY L: Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann. Intern. Med. (1999) 131(1):14-20.
64. PATRICK DM, ROSENTHAL SL, STANBERRY LR, HURST C, EBEL C: Patient satisfaction with care for genital herpes: insights from a global survey. Sex. Transm. Infect. (2004) 80(3):192-197.
65. ALEXANDER L, NAISBETT B: Patient and physician partnerships in managing genital herpes. J. Infect. Dis. (2002) 186(Suppl. 1):S57-S65.
66. WALD A, LANGENBERG A, LINK K et al.: Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 285:3100-3106.
67. SMITH JS, ROBINSON NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. (2002) 186(Suppl. 1):S3-S28.
68. SIEGAL F, LOPEZ C, HAMMER G et al.: Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. (1981) 305:1439-1444.
69. SCHACKER T: The role of HSV in the transmission and progression of HIV. Herpes (2001) 8(2):46-49.
70. AUGENBRAUN M, FELDMAN J, CHIRGWIN K et al.: Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann. Intern. Med. (1995) 123:845-847.
71. SCHACKER T, ZEH J, HU HL, HILL J, COREY L: Frequency of symptomatic and asymptomatic HSV-2 reactivations among HIV-infected men. J. Infect. Dis. (1998) 178:1616-1622.
72. POSAVAD CM, WALD A, KUNTZ S et al.: Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J. Infect. Dis. (2004) 190(4):693-696.
73. CONANT MA, SCHACKER TW, MURPHY RL et al.: Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int. J. STD AIDS (2002) 13(1):12-21.
74. GUPTA R, HILL EL, MCCLERNON D et al.: Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J. Infect. Dis. (2005) 192(6):1102-1107.
75. BACON TH, LEVIN MJ, LEARY JJ, SARISKY RT, SUTTON D: Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. (2003) 16(1):114-128.
76. SAFRIN S, ELBEIK T, PHAN L et al.: Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1994) 38:1246-1250.
77. The Red Book: Phamacy's Fundamental Reference. T Fleming (Ed.), Thomson Healthcare (2004):183, 346, 601.
78. FIFE KH, BARBARASH RA, RUDOLPH T, DEGREGORIO B, ROTH R: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind randomized clinical trial. Sex. Transm. Dis. (1997) 24:481-486.
79. SPRUANCE S, TRYING S, DEGREGORIO B et al.: A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch. Int. Med. (1996) 156:1729-1735.
80. SAIAG P, PRAINDHUI D, CHASTANG C: A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. J. Antimicrob. Chemother. (1999) 44(4):525-531.